不同剂量瑞舒伐他汀口服治疗冠心病心力衰竭疗效对比观察被引量：29

在线阅读下载PDF

导出

摘要目的观察不同剂量瑞舒伐他汀口服治疗冠心病心力衰竭的疗效,并探讨其可能机制。方法冠心病心力衰竭患者120例,随机分为A组、B组及对照组各40例。对照组予抗心力衰竭常规治疗;A、B组在常规治疗基础上分别给予10、20 mg瑞舒伐他汀口服。三组治疗8周后评价疗效。检测治疗前后左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)、血浆超敏C反应蛋白(hs-CRP)、N末端脑钠肽前体(NT-pro BNP),计算6分钟步行试验距离,观察药物不良反应。结果对照组、A组、B组总有效率分别为85.0%、90.0%、95.0%,A、B组总有效率与对照组相比,P均<0.05。三组治疗后LVESD、LVEDD、LVEF、6分钟步行试验距离均改善,血浆hs-CRP、NT-pro BNP水平降低;A、B组治疗后LVESD、LVEDD及血浆hs-CRP、NT-pro BNP水平低于对照组,LVEF、6分钟步行试验距离大于对照组(P均<0.05);B组LVESD、LVEDD及血浆hs-CRP、NTpro BNP低于A组,LVEF、6分钟步行试验距离大于A组(P均<0.05)。A、B组出现ALT轻度升高,未影响治疗;对照组未出现不良反应。结论瑞舒伐他汀口服治疗冠心病心力衰竭效果较好,其中20 mg剂量疗效优于10 mg。

作者董志华张炜

机构地区辽阳市中心医院

出处《山东医药》 CAS 北大核心 2015年第31期80-82,共3页 Shandong Medical Journal

关键词冠状动脉粥样硬化性心脏病心力衰竭瑞舒伐他汀超敏C反应蛋白 N末端脑钠肽前体

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献15

1Gandelman K,Fung GL,Messig M,et al.Systemic exposure to atorvastatin between Asian and Caucasian subjects:a combined analysis of 22 studies[J].Am J Ther,2012,19(3):164-173.
2Brunham LR,Lansberg PJ,Zhang L,et al.Diferential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin[J].Pharmacogenomics J,2012,12(3):233-237.
3Forteza A,Romano JG,Campo-Bustillo L,et al.High-dose atorvastatin enhances impaired cerebral vasomotor reactivity[J].J Stroke Cerebrovasc Dis,2012,21(6):487-492.
4Vaduganathan M,Greene SJ,Butler J,et al.The immunological axis in heart failure:importance of the leukocyte differential[J].Heart Fail Rev,2013,18(6):835-845.
5Nicholls SJ.Rosuvastatin and progression of atherosclerosis[J].Exper Rev Cardiovasc Ther,2008,6(7):925-933.
6Gürgün C,Ildizli M,Yavuzgil O,et al.The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure[J].Int J Cardiol,2008,123(2):102-107.
7Bittner V,Weiner DH,Yusuf S,et al.Prediction of mortality and morbidity with 6-minute walk test in patients with left ventricular dysfunction[J].JAMA,1993,270(14):1702-1707.
8Tsutamoto T,Tanaka T,Sakai H,et al.Total and high molecular weight adiponectin,haemodynamics,and mortality in patients with chronic heart failure[J].Eur Heart J,2007,28(14):1723-1730.
9卜晓佳,梁涛.6分钟步行试验在慢性心力衰竭患者中的应用进展[J].中国心血管杂志,2014,19(2):158-160. 被引量：52
10KozdagG,Ertas G,Kilic T,et al.Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure[J].Med Sci Monit,2010,16(3):156-161.